At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 60 target
Drug / intervention
ZG0895 Hydrochloride for Injectiondrug
Likely dose
ZG0895 Hydrochloride for Injection 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05877664Phase 1RecruitingMonitorUpdated 27mo ago · Completion was 1mo agoSlow Enrollment
Monitor
A Phase 1 Dose Escalation and Expansion, Tolerability, Safety, Pharmacokinetics / Pharmacodynamics and Preliminary Efficacy Study of ZG0895.HCl in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating ZG0895 Hydrochloride for Injection for Advanced Solid Tumor. Currently recruiting, targeting 60 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1RecruitingOverdue
202420252026
First PostedMay 2023
Enrollment StartAug 2023
Primary CompletionJun 2026
TodayJul 2026
First PostedMay 26, 2023
Enrollment StartAug 8, 2023
Primary CompletionJun 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 3.1 years ago
Interventions
ZG0895 Hydrochloride for Injectiondrug
The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)